The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma

被引:3
|
作者
Zhang, Lishuo [1 ]
Di, Longjiang [2 ]
Liu, Jinhui [3 ]
Lei, Xianli [4 ]
Gu, Maoli [1 ]
Zhang, Wenjing [3 ]
Wang, Yufu [3 ]
机构
[1] Harbin Med Univ, Dept Urol, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China
[2] Southern Med Univ, Coll Basic Med, Guangzhou, Guangdong, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Harbin, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; long non-coding RNA; cuproptosis; prognosis; immunotherapy; CLASSIFICATION;
D O I
10.3389/fgene.2023.1039813
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cuproptosis is a new form of cell death, the second form of metal ion-induced cell death defined after ferroptosis. Recently, cuproptosis has been suggested to be associated with tumorigenesis. However, the relationship between cuproptosis and patient prognosis in clear cell renal cell carcinoma (ccRCC) in the context of immunotherapy remains unknown. The aim of this study was to investigate the correlation between cuproptosis-related long non-coding RNA (lncRNA) and ccRCC in terms of immunity as well as prognosis. Clinical information on lncRNAs associated with differences in cuproptosis genes in ccRCC and normal tissues was collected from The Cancer Genome Atlas (TCGA) dataset. Univariate Cox regression was used to screen lncRNAs. A total of 11 lncRNAs closely associated with cuproptosis were further screened and established using the least absolute shrinkage and selection operator (LASSO) algorithm and multivariate Cox regression, and the samples were randomly divided into training and test groups. A risk prognostic model was constructed using the training group, and the model was validated using the test group. We investigated the predictive ability of the prognostic risk model in terms of clinical prognosis, tumor mutation, immune escape, immunotherapy, tumor microenvironment, immune infiltration levels, and tumor drug treatment of ccRCC. Using the median risk score, patients were divided into low and high-risk groups. Kaplan-Meier curves showed that the overall survival (OS) of patients in the high-risk group was significantly worse than low-risk group (p < 0.001). Receiver operating characteristic (ROC) curves further validated the reliability of our model. The model consistently and accurately predicted prognosis at 1, 3, and 5 years, with an AUC above 0.7. Tumor cell genes generally precede morphological abnormalities; therefore, the model we constructed can effectively compensate for the traditional method of evaluating the prognosis of patients with renal cancer, and our model was also clinically meaningful in predicting ccRCC staging. In addition, lower model risk scores determined by mutational load indicated a good chance of survival. The high-risk group had greater recruitment of immune cells, while the anti-immune checkpoint immunotherapy was less efficacious overall than that of the low-risk group. Tumor and immune-related pathways were enriched, and anti-tumor agents were selected to improve the survival of ccRCC. This prognostic risk model is based on the levels of cuproptosis-associated lncRNAs and provides a new perspective in the clinical assessment and precise treatment of ccRCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma
    Liu, Yanqing
    Jiang, Jianshuai
    CANCER BIOMARKERS, 2023, 37 (01) : 13 - 26
  • [12] Ferroptosis-associated lncRNA prognostic signature predicts prognosis and immune response in clear cell renal cell carcinoma
    Lai, Jiayi
    Miao, Shiqi
    Ran, Longke
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [13] A novel oxidative stress-related genes signature associated with clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma
    Wu, Xin
    Li, Fenghua
    Xie, Wenjie
    Gong, Binbin
    Fu, Bin
    Chen, Weimin
    Zhou, Libo
    Luo, Lianmin
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [14] Ferroptosis-associated lncRNA prognostic signature predicts prognosis and immune response in clear cell renal cell carcinoma
    Jiayi Lai
    Shiqi Miao
    Longke Ran
    Scientific Reports, 13
  • [15] The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma
    Sun, Peng
    Xu, Hua
    Zhu, Ke
    Li, Min
    Han, Rui
    Shen, Jiran
    Xia, Xingyuan
    Chen, Xiaojuan
    Fei, Guanghe
    Zhou, Sijing
    Wang, Ran
    FRONTIERS IN GENETICS, 2022, 13
  • [16] A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma
    Peng, Linjie
    Liang, Jiaming
    Wang, Qi
    Chen, Guodong
    FRONTIERS IN GENETICS, 2022, 13
  • [17] Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma
    Liang, Shuang
    Ji, Lanting
    Yu, Zhenyuan
    Cheng, Yahsin
    Gao, Ruifang
    Yan, Wenpeng
    Zhang, Fang
    HEREDITAS, 2024, 161 (01)
  • [18] Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma
    Shuang Liang
    Lanting Ji
    Zhenyuan Yu
    YaHsin Cheng
    Ruifang Gao
    Wenpeng Yan
    Fang Zhang
    Hereditas, 161
  • [19] EMILIN2 is associated with prognosis and immunotherapy in clear cell renal cell carcinoma
    Zhao, Guangjian
    Zheng, Jianpei
    Tang, Kai
    Chen, Qi
    FRONTIERS IN GENETICS, 2022, 13
  • [20] Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma
    Xu, Kangjie
    Li, Dongling
    Ji, Kangkang
    Zhang, Yanhua
    Zhang, Minglei
    Zhou, Hai
    Hou, Xuefeng
    Jiang, Jian
    Zhang, Zihang
    Dai, Hua
    Sun, Hang
    BIOLOGY DIRECT, 2024, 19 (01)